111 - References

References

438 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 5. Jiang HY, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-­ analysis. Clin Gastroenterol Hepatol 2015; 13:42–50. 6. Renoux C, et al. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 2017; 74:173–180. 7. Dalton SO, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-­based cohort study. Arch Intern Med 2003; 163:59–64. 8. Verdel BM, et al. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 2011; 89:89–96. 9. Tatsumi M, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249–258. 10. Weinrieb RM, et al. A critical review of selective serotonin reuptake inhibitor-­associated bleeding: balancing the risk of treating hepatitis C-­infected patients. J Clin Psychiatry 2003; 64:1502–1510. 11. Cheng YL, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-­based cohort study in Taiwan. Medicine (Baltimore) 2015; 94:e2022. 12. Meijer WE, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164:2367–2370. 13. Yuet WC, et al. Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding. J Am Osteopath Assoc 2019; 119:102–111. 14. van Walraven C, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323:655–658. 15. de Abajo FJ, et al. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-­inflammatory drugs and effect of acid-­suppressing agents. Arch Gen Psychiatry 2008; 65:795–803. 16. Lee MT, et al. Concomitant use of NSAIDs or SSRIs with NOACs requires monitoring for bleeding. Yonsei Med J 2020; 61:741–749. 17. Quinn GR, et al. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF trial. J Am Heart Assoc 2018; 7:e008755. 18. de Abajo FJ, et  al. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case–control study. BMJ 1999; 319:1106–1109. 19. Lewis JD, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17:328–335. 20. Axelsson MAB, et al. Bleeding in patients on concurrent treatment with a selective serotonin reuptake inhibitor (SSRI) and low-­dose acetylsalicylic acid (ASA) compared with SSRI or low-­dose ASA alone-­a systematic review and meta-­analysis. Br J Clin Pharmacol 2024; 90:916–932. 21. Alam SM, et al. Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-­analysis. Sci Rep 2022; 12:14452. 22. de Jong JC, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55:591–595. 23. Schalekamp T, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168:180–185. 24. Wallerstedt SM, et al. Risk of clinically relevant bleeding in warfarin-­treated patients: influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18:412–416. 25. Ziegelstein RC, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120:525–530. 26. Fernandes N, et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-­analysis. Clin Res Cardiol 2021; 110:183–193. 27. Meier CR, et al. Use of selective serotonin reuptake inhibitors and risk of developing first-­time acute myocardial infarction. Br J Clin Pharmacol 2001; 52:179–184. 28. Sauer WH, et al. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104:1894–1898. 29. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81–106. 30. Haghbin H, et al. Risk of gastrointestinal bleeding with concurrent use of NSAID and SSRI: a systematic review and network meta-­analysis. Dig Dis Sci 2023; 68:1975–1982. 31. Cheng YL, personal communication, 2017. 32. Wessinger S, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23:937–944. 33. Douros A, et al. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. CNS Drugs 2018; 32:321–334. 33. Liu L, et al. Selective serotonin reuptake inhibitors and intracerebral hemorrhage risk and outcome. Stroke 2020; 51:1135–1141. 35. Kubiszewski P, et al. Association of selective serotonin reuptake inhibitor use after intracerebral hemorrhage with hemorrhage recurrence and depression severity. JAMA Neurol 2020; 78:1–8. 36. Nochaiwong S, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-­analysis. Ann Med 2022; 54:80–97. 37. Shin JY, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-­steroidal anti-­inflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351:h3517.

Depression and anxiety disorders CHAPTER 3 38. Smoller JW, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 2009; 169:2128–2139. 39. Uguz F, et al. Antidepressants and menstruation disorders in women: a cross-­sectional study in three centers. Gen Hosp Psychiatry 2012; 34:529–533. 40. Andersohn F, et al. Citalopram-­induced bleeding due to severe thrombocytopenia. Psychosomatics 2009; 50:297–298. 41. Durmaz O, et al. Vaginal bleeding associated with antidepressants. Int J Gynaecol Obstet 2015; 130:284. 42. Turkoglu S, et al. Vaginal bleeding and hemorrhagic prepatellar bursitis in a preadolescent girl, possibly related to fluoxetine. J Child Adolesc Psychopharmacol 2015; 25:186–187. 43. Salkeld E, et  al. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008; 28:230–234. 43. Palmsten K, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013; 347:f4877. 45. Lindqvist PG, et al. Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital-­based cohort study. J Thromb Haemost 2014; 12:1986–1992. 46. Heller HM, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. BMC Pregnancy Childbirth 2017; 17:166. 47. Medicines and Healthcare products Regulatory Agency. Drug Safety Update. SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery. 2021 (last accessed February 2025); https://www.gov.uk/drug-­safety-­update/ ssri-­slash-­snri-­antidepressant-­medicines-­small-­increased-­risk-­of-­postpartum-­haemorrhage-­when-­used-­in-­the-­month-­before-­delivery? utm_source=e-­shot&utm_medium=email&utm_campaign=DSU_January2021split1. 48. Bobo WV, et al. The association of antidepressants in late pregnancy with postpartum hemorrhage: systematic review of controlled observational studies. J Child Adolesc Psychopharmacol 2024; 34:428–466. 49. Auerbach AD, et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013; 173:1075–1081. 50. Movig KL, et al. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163:2354–2358. 51. Liu B, et al. Use of selective serotonin-­reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351:1303–1307. 52. Richards JB, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188–194. 53. Leach MJ, et al. The risk of hip fracture due to mirtazapine exposure when switching antidepressants or using other antidepressants as add-­on therapy. Drugs Real World Outcomes 2017; 4:247–255. 54. Gylvin SH, et al. Psychopharmacologic treatment and blood transfusion in fast-­track total hip and knee arthroplasty. Transfusion 2017; 57:971–976. 55. Andreasen JJ, et al. Effect of selective serotonin reuptake inhibitors on requirement for allogeneic red blood cell transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs 2006; 6:243–250. 56. Basile FV, et al. Use of selective serotonin reuptake inhibitors antidepressants and bleeding risk in breast cosmetic surgery. Aesthetic Plast Surg 2013; 37:561–566. 57. Singh I, et al. Influence of pre-­operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-­analysis. Pharmacoepidemiol Drug Saf 2015; 24:237–245. 58. Hoveidaei AH, et al. Preoperative SSRI use increases perioperative transfusion need in patients undergoing surgical procedures on the hip joint. Eur J Orthop Surg Traumatol 2024; 34:3903–3908. 59. Mahdanian AA, et  al. Serotonergic antidepressants and perioperative bleeding risk: a systematic review. Expert Opin Drug Saf 2014; 13:695–704. 60. Jeong BO, et al. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics 2014; 55:213–220. 61. Perahia DG, et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-­inflammatory drugs (NSAIDs): analysis of placebo-­controlled trials and post-­marketing adverse event reports. Drug Healthc Patient Saf 2013; 5:211–219. 62. Bixby AL, et al. Clinical management of bleeding risk with antidepressants. Ann Pharmacother 2019; 53:186–194. 63. Halperin D, et al. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9:47–59. 64. Na K-­S, et al. Can we recommend mirtazapine and bupropion for patients at risk for bleeding? A systematic review and meta-­analysis. J Affect Disord 2018; 225:221–226. 65. Machado CM, et al. Impact of selective serotonin-­reuptake inhibitors in hemorrhagic risk in anticoagulated patients taking non-­vitamin K antagonist anticoagulants: a systematic review and meta-­analysis. J Clin Psychopharmacol 2023; 43:267–272. 66. Rahman AA, et al. Concomitant use of selective serotonin reuptake inhibitors and oral anticoagulants and risk of major bleeding: a systematic review and meta-­analysis. Thromb Haemost 2023; 123:54–63.